君实生物今日盘中股价大幅上涨5.11%，市场表现活跃。
消息面上，多重利好因素共同推动了股价上涨。首先，在全球肿瘤学盛会AACR年会期间，公司核心管线JS207（PD-1/VEGF双抗）披露了两项II期联合治疗的积极临床数据，并有望在年内进入关键注册临床阶段；另一款核心管线JS212（EGFR/HER3 ADC）也披露了早期数据，计划于年底启动关键注册临床。其次，太平洋证券发布研报，上调公司目标价至53.12元，并给予“买入”评级。此外，公司第三大股东减持计划期满并未实施减持，叠加公司全年营收同比增长28.23%、核心产品特瑞普利单抗销售额增长超40%的积极财务表现，进一步提振了市场信心。
另据相关报道，君实生物的全资子公司君实香港作为基石投资者，参与了迈威生物-B的港股招股，认购总额达5300万美元，这也显示了公司在生物医药领域的战略布局与资本影响力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.